- Home
- CAPR vs UMAC Comparison
CAPR vs UMAC Comparison
Compare CAPR & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- UMAC
- Stock Information
- Founded
- CAPR 2005
- UMAC 2019
- Country
- CAPR United States
- UMAC United States
- Employees
- CAPR N/A
- UMAC N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- UMAC
- Sector
- CAPR Health Care
- UMAC
- Exchange
- CAPR Nasdaq
- UMAC Nasdaq
- Market Cap
- CAPR 322.7M
- UMAC 267.7M
- IPO Year
- CAPR N/A
- UMAC 2024
- Fundamental
- Price
- CAPR $7.10
- UMAC $11.03
- Analyst Decision
- CAPR Strong Buy
- UMAC Strong Buy
- Analyst Count
- CAPR 8
- UMAC 3
- Target Price
- CAPR $24.75
- UMAC $17.67
- AVG Volume (30 Days)
- CAPR 1.7M
- UMAC 2.6M
- Earning Date
- CAPR 08-11-2025
- UMAC 08-14-2025
- Dividend Yield
- CAPR N/A
- UMAC N/A
- EPS Growth
- CAPR N/A
- UMAC N/A
- EPS
- CAPR N/A
- UMAC N/A
- Revenue
- CAPR $13,392,150.00
- UMAC $7,701,550.00
- Revenue This Year
- CAPR $16.24
- UMAC $100.69
- Revenue Next Year
- CAPR $328.11
- UMAC $93.15
- P/E Ratio
- CAPR N/A
- UMAC N/A
- Revenue Growth
- CAPR N/A
- UMAC 279.38
- 52 Week Low
- CAPR $3.98
- UMAC $1.28
- 52 Week High
- CAPR $23.40
- UMAC $23.62
- Technical
- Relative Strength Index (RSI)
- CAPR 42.24
- UMAC 58.79
- Support Level
- CAPR $6.90
- UMAC $8.95
- Resistance Level
- CAPR $8.00
- UMAC $10.72
- Average True Range (ATR)
- CAPR 0.55
- UMAC 0.93
- MACD
- CAPR -0.02
- UMAC 0.02
- Stochastic Oscillator
- CAPR 7.91
- UMAC 85.26
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.